Department of Endocrinology, Henan University People's Hospital; Henan Provincial People's Hospital, Zhengzhou, Henan 450003, China.
State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.
Chin Med J (Engl). 2020 Apr 5;133(7):808-816. doi: 10.1097/CM9.0000000000000696.
Metabolic syndrome (MetS) describes a set of risk factors that can eventually lead to the occurrence of cardiovascular and cerebrovascular disease. A detailed understanding of the MetS mechanism will be helpful in developing effective prevention strategies and appropriate intervention tools. In this article, we discuss the relationship between the clinical symptoms of MetS and differences in the gut microbial community compared with healthy individuals, characterized by the proliferation of potentially harmful bacteria and the inhibition of beneficial ones. Interactions between gut microbiota and host metabolism have been shown to be mediated by a number of factors, including inflammation caused by gut barrier defects, short-chain fatty acids metabolism, and bile acid metabolism. However, although we can clearly establish a causal relationship between gut microbial profiles and MetS in animal experiments, the relationship between them is still controversial in humans. Therefore, we need more clinical studies to augment our understanding of how we can manipulate the gut microbiota and address the role of the gut microbiota in the prevention and treatment of MetS.
代谢综合征（Metabolic syndrome，MetS）描述了一组可导致心脑血管疾病发生的风险因素。深入了解 MetS 的发病机制有助于制定有效的预防策略和适当的干预手段。本文讨论了 MetS 的临床症状与健康个体之间肠道微生物群落的差异之间的关系，其特征是潜在有害细菌的增殖和有益细菌的抑制。肠道微生物群与宿主代谢之间的相互作用是由多种因素介导的，包括由肠道屏障缺陷引起的炎症、短链脂肪酸代谢和胆汁酸代谢。然而，尽管我们可以在动物实验中明确建立肠道微生物群与 MetS 之间的因果关系，但它们在人类中的关系仍存在争议。因此，我们需要更多的临床研究来加深我们对如何操纵肠道微生物群以及肠道微生物群在预防和治疗 MetS 中的作用的理解。
